New shot aims to stop RSV before it starts
NCT ID NCT07106918
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing an experimental drug called SIBP-A16 in 140 healthy adults aged 18 to 45. The goal is to see if it is safe and how the body handles it. Participants receive a single injection of the drug, a placebo, or an existing RSV antibody. The study does not yet test whether it actually prevents RSV illness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SIBP-A16 injection (an experimental biologic)
- What this could lead to
- If successful, this could lead to a new option to prevent RSV infection in healthy adults.
- What could go wrong
- This is an early Phase 1 trial focused on safety, not effectiveness. It is small and may not show benefit or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wuhan Jinyintan Hospital
RECRUITINGWuhan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One shot, two viruses? new mRNA vaccine targets RSV and hMPV
- New mRNA vaccine aims to shield against RSV
- Massive RSV vaccine study uses real-world data to see if shots prevent severe illness
- New RSV vaccine aims to shield adults from severe respiratory infection
- Scientists test RSV vaccine to boost immune memory
- New study tracks RSV in pregnant women and their babies